Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis

Current Opinion in Cardiology

Volumn 31, Issue 4, 2016, Pages 440-450

  Yeang, Calvin ^a   Wilkinson, Michael J ^a   Tsimikas, Sotirios ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

Animal models; Aortic stenosis; Apo(a); Lipoprotein(a); Oxidized phospholipids

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHOLIPID;

AORTA VALVE REPLACEMENT; AORTA VALVE STENOSIS; CALCIFICATION; DISEASE ASSOCIATION; DISEASE COURSE; GENETICS; HUMAN; NONHUMAN; PATHOGENESIS; PHASE 2 CLINICAL TRIAL (TOPIC); PREDICTIVE VALUE; PRIORITY JOURNAL; REVIEW; ANTAGONISTS AND INHIBITORS; AORTIC VALVE; AORTIC VALVE STENOSIS; BLOOD; CALCINOSIS; GENOME-WIDE ASSOCIATION STUDY; PATHOLOGY;

AORTIC VALVE; AORTIC VALVE STENOSIS; CALCINOSIS; GENOME-WIDE ASSOCIATION STUDY; HUMANS; LIPOPROTEIN(A); PHOSPHOLIPIDS;

EID: 84969592223     PISSN: 02684705     EISSN: 15317080     Source Type: Journal    
DOI: 10.1097/HCO.0000000000000300     Document Type: Review

References (95)

1. Yutzey KE, Demer LL, Body SC, et al. Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. Arterioscler Thromb Vasc Biol 2014; 34:2387-2393.
2. Otto CM, Prendergast B. Aortic-valve stenosis - from patients at risk to severe valve obstruction. N Engl J Med 2014; 371:744-756.
3. Pawade TA, Newby DE, Dweck MR. Calcification in aortic stenosis. The skeleton key. J Am Coll Cardiol 2015; 66:561-577. Excellent review article on the role of calcification in aortic stenosis.
4. Cowell SJ, Newby DE, Prescott RJ, et al. A randomized trial of intensive lipidlowering therapy in calcific aortic stenosis. N Engl J Med 2005; 352:2389-2397.
5. Rossebo AB, Pedersen TR, Boman K, et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. N Engl J Med 2008; 359:1343-1356.
6. Chan KL, Teo K, Dumesnil JG, et al. Effect of lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010; 121:306-314.
7. Dichtl W, Alber HF, Feuchtner GM, et al. Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). Am J Cardiol 2008; 102:743-748.
8. Gotoh T, Kuroda T, Yamasawa M, et al. Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). Am J Cardiol 1995; 76:928-932.
9. Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29:630-634.
10. Glader CA, Birgander LS, Soderberg S, et al. Lipoprotein(a), Chlamydia pneumoniae, leptin and tissue plasminogen activator as risk markers for valvular aortic stenosis. Eur Heart J 2003; 24:198-208.
11. Bozbas H, Yildirir A, Atar I, et al. Effects of serum levels of novel atherosclerotic risk factors on aortic valve calcification. J Heart Valve Dis 2007; 16:387-393.
12. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014; 63:470-477. Mendelian randomization analysis within the CGPS and CCHS cohorts (n=77 680) demonstrating an Lp(a) dose dependent risk for aortic valve stenosis, with a hazard ratio of 1.6 for each 10-fold increase in genetically determined Lp(a) levels associated with the LPA SNPs rs10455872 and rs3798220 or kringle IV type 2 repeats.
13. Langsted A, Varbo A, Kamstrup PR, Nordestgaard BG. Elevated lipoprotein( a) does not cause low-grade inflammation despite causal association with aortic valve stenosis and myocardial infarction: a study of 100, 578 individuals from the general population. J Clin Endocrinol Metab 2015; 100:2690-2699.
14. Arsenault BJ, Boekholdt SM, Dube MP, et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 2014; 7:304-310.
15. Vongpromek R, Bos S, Ten Kate GJ, et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med 2015; 278:166-173.
16. Capoulade R, Chan KL, Yeang C, et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 2015; 66:1236-1246. This study demonstrated that elevated Lp(a) (>58.5 mg/dl) as well as OxPL-apoB (>5.50 nM) are each associated with 1.5 times faster progression of aortic valve stenosis and a two-fold increased risk of AVR and death, in a secondary analysis of 220 patients from the ASTRONOMER trial followed for an average of 3.5 years.
17. Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368:503-512.
18. Smith JG, Luk K, Schulz CA, et al. Association of low-density lipoprotein cholesterol-related genetic variants with aortic valve calcium and incident aortic stenosis. JAMA 2014; 312:1764-1771.
19. Yeang C, Witztum JL, Tsimikas S. 'LDL-C'=LDL-C+Lp(a)-C: implications of achieved ultra-low LDL-C levels in the proprotein convertase subtilisin/kexin type 9 era of potent LDL-C lowering. Curr Opin Lipidol 2015; 26:169-178.
20. Moura LM, Ramos SF, Zamorano JL, et al. Rosuvastatin affecting aortic valve endothelium to slow the progression of aortic stenosis. J Am Coll Cardiol 2007; 49:554-561.
21. Teo KK, Corsi DJ, Tam JW, et al. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients. Can J Cardiol 2011; 27:800-808.
22. Antonini-Canterin F, Hirsu M, Popescu BA, et al. Stage-related effect of statin treatment on the progression of aortic valve sclerosis and stenosis. Am J Cardiol 2008; 102:738-742.
23. Postmus I, Trompet S, Deshmukh HA, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun 2014; 5:1-10.
24. Donnelly LA, van Zuydam NR, Zhou K, et al. Robust association of the LPA locus with low-density lipoprotein cholesterol lowering response to statin treatment in a meta-analysis of 30 467 individuals from both randomized control trials and observational studies and association with coronary artery disease outcome during statin treatment. Pharmacogenet Genomics 2013; 23:518-525.
25. Deshmukh HA, Colhoun HM, Johnson T, et al. Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a). J Lipid Res 2012; 53:1000-1011.
26. Nordestgaard BG, Chapman MJ, Ray K, et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31:2844-2853.
27. Tziomalos K, Athyros VG, Wierzbicki AS, Mikhailidis DP. Lipoprotein a: where are we now? Curr Opin Cardiol 2009; 24:351-357.
28. Yeang C, Hung MY, Byun YS, et al. Effect of therapeutic interventions on oxidized phospholipids on apolipoprotein B-100 and lipoprotein(a). J Clin Lipidol. (in press).
29. Dweck MR, Boon NA, Newby DE. Calcific aortic stenosis: a disease of the valve and the myocardium. J Am Coll Cardiol 2012; 60:1854-1863.
30. Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999; 19:1218-1222.
31. O'Brien KD, Reichenbach DD, Marcovina SM, et al. Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. Arterioscler Thromb Vasc Biol 1996; 16:523-532.
32. Otto CM, Kuusisto J, Reichenbach DD, et al. Characterization of the early lesion of 'degenerative' valvular aortic stenosis. Histological and immunohistochemical studies. Circulation 1994; 90:844-853.
33. Lou XJ, Boonmark NW, Horrigan FT, et al. Fibrinogen deficiency reduces vascular accumulation of apolipoprotein(a) and development of atherosclerosis in apolipoprotein(a) transgenic mice. Proc Natl Acad Sci U S A 1998; 95:12591-12595.
34. Hughes SD, Lou XJ, Ighani S, et al. Lipoprotein(a) vascular accumulation in mice. In vivo analysis of the role of lysine binding sites using recombinant adenovirus. J Clin Invest 1997; 100:1493-1500.
35. Loscalzo J, Weinfeld M, Fless GM, Scanu AM. Lipoprotein(a), fibrin binding, and plasminogen activation. Arterioscler Thromb Vasc Biol 1990; 10:240-245.
36. Leibundgut G, Scipione C, Yin H, et al. Determinants of binding of oxidized phospholipids on apolipoprotein(a) and lipoprotein(a). J Lipid Res 2013; 54:2815-2830.
37. Arai K, Orsoni A, Mallat Z, et al. Acute impact of apheresis on oxidized phospholipids in patients with familial hypercholesterolemia. J Lipid Res 2012; 53:1670-1678.
38. Yoshida H, Shoda T, Yanai H, et al. Effects of pitavastatin and atorvastatin on lipoprotein oxidation biomarkers in patients with dyslipidemia. Atherosclerosis 2013; 226:161-164.
39. Bergmark C, Dewan A, Orsoni A, et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008; 49:2230-2239.
40. Edelstein C, Pfaffinger D, Yang M, et al. Naturally occurring human plasminogen, like genetically related apolipoprotein(a), contains oxidized phosphatidylcholine adducts. Biochim Biophys Acta 2010; 1801:738-745.
41. Leibundgut G, Arai K, Orsoni A, et al. Oxidized phospholipids are present on plasminogen, affect fibrinolysis, and increase following acute myocardial infarction. J Am Coll Cardiol 2012; 59:1426-1437.
42. Tsimikas S, Clopton P, Brilakis ES, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 particles to race/ethnicity, apolipoprotein(a) isoform size, and cardiovascular risk factors: results from the Dallas Heart Study. Circulation 2009; 119:1711-1719.
43. Rao F, Schork AJ, Maihofer AX, et al. Heritability of biomarkers of oxidized lipoproteins: twin pair study. Arterioscler Thromb Vasc Biol 2015; 35:1704-1711.
44. Byun YS, Lee JH, Arsenault BJ, et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 2015; 65:1286-1295.
45. Arai K, Luke MM, Koschinsky ML, et al. The I4399M variant of apolipoprotein( a) is associated with increased oxidized phospholipids on apolipoprotein B-100 particles. Atherosclerosis 2010; 209:498-503.
46. Ky B, Burke A, Tsimikas S, et al. The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 2008; 51:1653-1662.
47. Choi SH, Chae A, Miller E, et al. Relationship between biomarkers of oxidized low-density lipoprotein, statin therapy, quantitative coronary angiography, and atheroma: volume observations from the REVERSAL (Reversal of Atherosclerosis with Aggressive Lipid Lowering) study. J Am Coll Cardiol 2008; 52:24-32.
48. Rodenburg J, Vissers MN, Wiegman A, et al. Oxidized low-density lipoprotein in children with familial hypercholesterolemia and unaffected siblings: effect of pravastatin. J Am Coll Cardiol 2006; 47:1803-1810.
49. Tsimikas S, Witztum JL, Miller ER, et al. High-dose atorvastatin reduces total plasma levels of oxidized phospholipids and immune complexes present on apolipoprotein B-100 in patients with acute coronary syndromes in the MIRACL trial. Circulation 2004; 110:1406-1412.
50. Faghihnia N, Tsimikas S, Miller ER, et al. Changes in lipoprotein(a), oxidized phospholipids, and LDL subclasses with a low-fat high-carbohydrate diet. J Lipid Res 2010; 51:3324-3330.
51. Budoff MJ, Ahmadi N, Gul KM, et al. Aged garlic extract supplemented with B vitamins, folic acid and L-arginine retards the progression of subclinical atherosclerosis: a randomized clinical trial. Prev Med 2009; 49:101-107.
52. Silaste ML, Rantala M, Alfthan G, et al. Changes in dietary fat intake alter plasma levels of oxidized low-density lipoprotein and lipoprotein(a). Arterioscler Thromb Vasc Biol 2004; 24:498-503.
53. Tsimikas S, Viney NJ, Hughes SG, et al. Antisense therapy targeting apolipoprotein( a): a randomised, double-blind, placebo-controlled phase 1 study. Lancet 2015; 386:1472-1483.
54. Miller YI, Choi S-H, Wiesner P, et al. Oxidation-specific epitopes are dangerassociated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ Res 2011; 108:235-248.
55. Witztum JL, Lichtman AH. The influence of innate and adaptive immune responses on atherosclerosis. Annu Rev Pathol 2014; 9:73-102.
56. Horkko S, Bird DA, Miller E, et al. Monoclonal autoantibodies specific for oxidized phospholipids or oxidized phospholipid-protein adducts inhibit macrophage uptake of oxidized low-density lipoproteins. J Clin Invest 1999; 103:117-128.
57. Palinski W, Horkko S, Miller E, et al. Cloning of monoclonal autoantibodies to epitopes of oxidized lipoproteins from apolipoprotein E-deficient mice. Demonstration of epitopes of oxidized low density lipoprotein in human plasma. J Clin Invest 1996; 98:800-814.
58. Friedman P, Horkko S, Steinberg D, et al. Correlation of antiphospholipid antibody recognition with the structure of synthetic oxidized phospholipids. Importance of Schiff base formation and aldol condensation. J Biol Chem 2002; 277:7010-7020.
59. Wu R, de Faire U, Lemne C, et al. Autoantibodies to OxLDL are decreased in individuals with borderline hypertension. Hypertension 1999; 33: 53-59.
60. Tsimikas S, Mallat Z, Talmud PJ, et al. Oxidation-specific biomarkers, lipoprotein( a), and risk of fatal and nonfatal coronary events. J Am Coll Cardiol 2010; 56:946-955.
61. Kiechl S, Willeit J, Mayr M, et al. Oxidized phospholipids, lipoprotein(a), lipoprotein-associated phospholipase A2 activity, and 10-year cardiovascular outcomes: prospective results from the Bruneck study. Arterioscler Thromb Vasc Biol 2007; 27:1788-1795.
62. Ahmadi N, Tsimikas S, Hajsadeghi F, et al. Relation of oxidative biomarkers, vascular dysfunction, and progression of coronary artery calcium. Am J Cardiol 2010; 105:459-466.
63. Tsimikas S, Kiechl S, Willeit J, et al. Oxidized phospholipids predict the presence and progression of carotid and femoral atherosclerosis and symptomatic cardiovascular disease: five-year prospective results from the Bruneck study. J Am Coll Cardiol 2006; 47:2219-2228.
64. Tsimikas S, Brilakis ES, Miller ER, et al. Oxidized phospholipids, Lp(a) lipoprotein, and coronary artery disease. N Engl J Med 2005; 353:46-57.
65. Tsimikas S, Bergmark C, Beyer RW, et al. Temporal increases in plasma markers of oxidized low-density lipoprotein strongly reflect the presence of acute coronary syndromes. J Am Coll Cardiol 2003; 41:360-370.
66. Tsimikas S, Lau HK, Han KR, et al. Percutaneous coronary intervention results in acute increases in oxidized phospholipids and lipoprotein(a): short-term and long-term immunologic responses to oxidized low-density lipoprotein. Circulation 2004; 109:3164-3170.
67. Mody N, Parhami F, Sarafian TA, Demer LL. Oxidative stress modulates osteoblastic differentiation of vascular and bone cells. Free Radic Biol Med 2001; 31:509-519.
68. Maziere C, Louvet L, Gomila C, et al. Oxidized low density lipoprotein decreases Rankl-induced differentiation of osteoclasts by inhibition of Rankl signaling. J Cell Physiol 2009; 221:572-578.
69. Derwall M, Malhotra R, Lai CS, et al. Inhibition of bone morphogenetic protein signaling reduces vascular calcification and atherosclerosis. Arterioscler Thromb Vasc Biol 2012; 32:613-622.
70. Tsimikas S, Miller YI. Oxidative modification of lipoproteins: mechanisms, role in inflammation and potential clinical applications in cardiovascular disease. Curr Pharm Des 2011; 17:27-37.
71. Stewart CR, Stuart LM, Wilkinson K, et al. CD36 ligands promote sterile inflammation through assembly of a Toll-like receptor 4 and 6 heterodimer. Nat Immunol 2010; 11:155-161.
72. Afonyushkin T, Oskolkova OV, Philippova M, et al. Oxidized phospholipids regulate expression of ATF4 and VEGF in endothelial cells via NRF2-dependent mechanism: novel point of convergence between electrophilic and unfolded protein stress pathways. Arterioscler Thromb Vasc Biol 2010; 30:1007-1013.
73. Bochkov VN. Inflammatory profile of oxidized phospholipids. Thromb Haemost 2007; 97:348-354.
74. Scipione CA, Sayegh SE, Romagnuolo R, et al. Mechanistic insights into Lp(a)-induced IL-8 expression: a role for oxidized phospholipid modification of apo(a). J Lipid Res 2015; 56:2273-2285. The authors show that apo(a) containing OxPL induces proinflammatory IL-8 expression, whereas mutant apo(a) and apo(a) treated with Lp-PLA2, both lacking OxPL, do not upregulate this cytokine. This is one example of how OxPL reflects the biological activity of Lp(a).
75. Cola C, Almeida M, Li D, et al. Regulatory role of endothelium in the expression of genes affecting arterial calcification. Biochem Biophys Res Commun 2004; 320:424-427.
76. Su X, Ao L, Shi Y, et al. Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4. J Biol Chem 2011; 286:12213-12220.
77. Nadlonek NA, Lee JH, Weyant MJ, et al. ox-LDL induces PiT-1 expression in human aortic valve interstitial cells. J Surg Res 2013; 184:6-9.
78. Goettsch C, Rauner M, Hamann C, et al. Nuclear factor of activated T cells mediates oxidised LDL-induced calcification of vascular smooth muscle cells. Diabetologia 2011; 54:2690-2701.
79. Liao L, Zhou Q, Song Y, et al. Ceramide mediates Ox-LDL-induced human vascular smooth muscle cell calcification via p38 mitogen-activated protein kinase signaling. PLoS One 2013; 8:1-10.
80. Syvaranta S, Alanne-Kinnunen M, Oorni K, et al. Potential pathological roles for oxidized low-density lipoprotein and scavenger receptors SR-AI, CD36, and LOX-1 in aortic valve stenosis. Atherosclerosis 2014; 235:398-407.
81. Bennett BJ, Scatena M, Kirk EA, et al. Osteoprotegerin inactivation accelerates advanced atherosclerotic lesion progression and calcification in older ApoE-/- mice. Arterioscler Thromb Vasc Biol 2006; 26:2117-2124.
82. Morony S, Tintut Y, Zhang Z, et al. Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice. Circulation 2008; 117:411-420.
83. Parhami F, Morrow AD, Balucan J, et al. Lipid oxidation products have opposite effects on calcifying vascular cell and bone cell differentiation. A possible explanation for the paradox of arterial calcification in osteoporotic patients. Arterioscler Thromb Vasc Biol 1997; 17:680-687.
84. Yan J, Stringer SE, Hamilton A, et al. Decorin GAG synthesis and TGF-beta signaling mediate Ox-LDL-induced mineralization of human vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2011; 31:608-615.
85. Palinski W, Yla-Herttuala S, Rosenfeld ME, et al. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. Arteriosclerosis 1990; 10:325-335.
86. Tintut Y, Patel J, Territo M, et al. Monocyte/macrophage regulation of vascular calcification in vitro. Circulation 2002; 105:650-655.
87. Blencowe C, Hermetter A, Kostner GM, Deigner HP. Enhanced association of platelet-activating factor acetylhydrolase with lipoprotein (a) in comparison with low density lipoprotein. J Biol Chem 1995; 270:31151-31157.
88. Mahmut A, Boulanger MC, El Husseini D, et al. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol 2014; 63:460-469.
89. Bouchareb R, Mahmut A, Nsaibia MJ, et al. Autotaxin derived from lipoprotein( a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation 2015; 132:677-690. This study demonstrated that Lp(a) is present in stenotic human aortic valves and co-localized with OxPL, Lp-PLA2, and autotaxin (an enzyme that hydrolyzes lysophosphatidylcholine to LPA). LPA induces calcification by VIC in vitro and promotes aortic valve calcification in a mouse model of aortic valve stenosis. These findings add to the understanding of how Lp(a) and its lipid cargo mediate calcific aortic valve stenosis.
90. Miller JD, Weiss RM, Heistad DD. Calcific aortic valve stenosis: methods, models, and mechanisms. Circ Res 2011; 108:1392-1412.
91. Miller JD, Weiss RM, Serrano KM, et al. Lowering plasma cholesterol levels halts progression of aortic valve disease in mice. Circulation 2009; 119:2693-2701.
92. Schneider M, Witztum JL, Young SG, et al. High-level lipoprotein [a] expression in transgenic mice: evidence for oxidized phospholipids in lipoprotein [a] but not in low density lipoproteins. J Lipid Res 2005; 46:769-778.
93. Albers JJ, Slee A, O'Brien KD, et al. Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). J Am Coll Cardiol 2013; 62:1575-1579.
94. Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010; 363:2406-2415.
95. ClinicalTrials.gov. Thanassoulis G. Early Aortic Valve Lipoprotein(a) Lowering Trial (EAVaLL): a pilot, randomized controlled-trial of lipoprotein(a) lowering for the prevention of aortic valve disease-translating genomic knowledge for cardiovascular prevention. 2015. https://clinicaltrials.gov/ct2/show/study/ NCT02109614. [Accessed 11 February 2016].